A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas.
Julie I KrystalDerek HansonDanielle DonnellyMark AtlasPublished in: Pediatric blood & cancer (2024)
Mebendazole was safe and well tolerated when administered with bevacizumab and irinotecan at doses up to 200 mg/kg/day. Further studies are needed to determine the efficacy of this treatment.